肺腺癌胸苷酸合成酶表达与放射敏感性的关系
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2018年18期
- 页码:
- 2863-2866
- 栏目:
- 论著（胸部肿瘤）
- 出版日期:
- 2018-08-08
文章信息/Info
- Title:
- The relationship between thymidylate synthase expression and radiosensitivity of lung adenocarcinoma
- Author(s):
- Su Lin1; Su Jiali2; Cai Weiwei2
- 1.Department of Oncology,Central South University Xiangya Hospital,Hunan Changsha 410008,China;2.Department of Oncology,The Second Affiliated Hospital of Hunan Normal University,No.163 Hospital of PLA,Hunan Changsha 410003,China.
- Keywords:
- lung neoplasms; adenocarcinoma; thymidylate synthetase; stereotactic conformal radiotherapy; body gamma-knife; radiosensitivity
- 分类号:
- R734.2
- DOI:
- 10.3969/j.issn.1672-4992.2018.18.010
- 文献标识码:
- A
- 摘要:
- 目的：探讨肺腺癌患者胸苷酸合成酶（TS）不同表达水平与放射敏感性的关系。方法:对经病理确诊的94例局部晚期肺腺癌患者，根据TS不同表达水平，将患者分为高表达组(40例)和低表达组（54例）。对患者的肺部原发病灶行体部伽玛刀立体定向适形放射治疗，放疗结束后１个月复查胸部CT评价近期疗效。结果:全部患者均按计划完成治疗，两组近期疗效：高表达组：CR 3例，PR 27例，SD 7例，PD 3例，近期总有效率为75.0%［(CR+PR)/总病例数×100%］；低表达组：CR 8例，PR 41例，SD 3例，PD 2例，近期总有效率为90.7%。两组近期疗效比较差异有统计学意义（P＜0.05）。结论:肺腺癌TS低表达组的放疗后近期疗效好，提示TS表达水平可能作为肺腺癌放射敏感性的标志物之一。
- Abstract:
- Objective:To investigate the relationship between the levels of thymidylate synthetase(TS) and radiosensitivity in patients with lung adenocarcinoma.Methods:Atotal of 94 patients with locally advanced lung adenocarcinoma confirmed by pathology were divided into high expression group(40 cases) and low expression group(54 cases) according to the different expression level of TS.The patients' primary lung lesions were treated with body gamma knife stereotactic radiotherapy,and 1 months after the end of the radiotherapy,the immediate effect of the chest CT was reviewed.Results:All the patients completed the treatment according to the plan.The short-term efficacy of the two groups were as follows:In high expression group with CR 3 cases,PR 27 cases,SD 7 cases and PD 3 cases,the total effective rate was 75.0%［(CR+PR)/total cases×100%］.In low expression group with CR 8 cases,PR 41 cases,SD 3 cases,and PD 2 cases,the recent total effective rate was 90.7%.There was a significant difference in the recent curative effect between the two groups(P＜0.05).Conclusion:The short term radiotherapy effect of TS low expression group of lung adenocarcinoma is good,suggesting that the expression level of TS may be one of the markers of radiosensitivity of lung adenocarcinoma.
参考文献/References
[1] Torre LA,Bray F,Siegel RL,et al.Global cancer statistic,2012［J］.CA:A Cancer Journal for Clinicians,2015,65(2):87-108.
[2] Chen WQ,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
[3]SaadeddinA.Radiotherapy for NSCLC:Review of conventional and new treatment techniques［J］.J Infect Public Health,2012,5(5):S45-S49.
[4] Yang M,Fan W,Pu X,et al.The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy［J］.Journal of Chemotherapy,2017,29(2):106-112.
[5] Liu D,Nakashima N,Nakano JUN,et al.Customized adjuvant chemotherapy based on biomarker examination may improve survival of patients completely resected for non-small-cell lung cancer［J］.Anticancer Research,2017,37(5):2501-2507.
[6]Feng Xiemin,Zhong Hong,Hu Yunfeng,et al.The relationship between thymidylate synthetase and pemetrexed therapy in the treatment of lung adenocarcinoma ［J］.Chinese Journal of Physicians,2017,19(2):243-249.［冯谢敏,赵红,胡云峰,等.胸苷酸合成酶与培美曲塞治疗肺腺癌疗效的关系［J］.中国医师杂志,2017,19(2):243-249.］
[7] Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer:A pooled analysis of two randomised trials［J］.Lancet Oncology,2015,16(6):630-637.
[8] Wang Weixing,Yang Bo,Yu Lifang,et al.Expression of PKM2 in non-small cell lung cancer and its relationship with radiotherapy sensitivity analysis ［J］.Hebei Medicine,2017,39（4）:504-507.［王伟星,杨波,余丽芳,等.非小细胞肺癌PKM2的表达及与放疗敏感性的关系分析［J］.河北医药,2017,39(4):504-507.］
[9] Zhou Y,Liao Q,Han Y,et al.Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer［J］.Journal of Cancer,2016,7(14):2100-2109.
[10] Su Jiali,Zhu Daoqi,Yang Yu.The relationship between mutation of epidermal growth factor receptor tyrosine kinase domain and radiosensitivity in patients with lung adenocarcinoma［J］.Medical Clinical Study,2014,31(6):1062-1064.［苏加利,朱道奇,杨妤.肺腺癌患者表皮生长因子受体酪氨酸激酶结构域突变与放射敏感性的关系［J］.医学临床研究,2014,31(6):1062-1064.］
[11] Xin L,Yan L,Jin W,et al.LHX3 is an early stage and radiosensitivity prognostic biomarker in lung adenocarcinoma［J］.Oncology Reports,2017，38(3):1482-1490.
[12] Jiang X,Zhang QL,Tian YH,et al.RNA interference-mediated gene silencing of cyclophilin A enhances the radiosensitivity of PAa human lung adenocarcinoma cells in vitro［J］.Oncology Letters,2017,13(3):1619-1624.
[13] Saga Y,Suzuki M,Mizukami H,et al.Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation［J］.Oncology,2002,63(2):185-191.
[14] Hori T,Takahashi E,Ayusawa D,et al.Regional assignment of the human thymidylate synthase(TS) gene to chromosome band 18p11.32 by nonisotopic in situ hybridization［J］.Human Genetics,1990,85(6):576-580.
[15] Chen Jingtang.Expression of thymidylate synthase and ribonucleotide reductase M1 in advanced non squamous non-small cell lung cancer and its relationship with chemotherapy efficacy ［J］.Guangxi Medicine,2016,38(7):945-947.［陈镜塘.晚期非鳞非小细胞肺癌胸苷酸合成酶和核糖核苷酸还原酶M1的表达及其与化疗疗效的关系［J］.广西医学,2016,38(7):945-947.］
[16] Cardona AF,Rojas L,Wills B,et al.Pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab in hispanic patients with non-squamous non-small cell lung cancer:Outcomes according to thymidylate synthase expression［J］.PLoS One,2016,11(5):e0154293.
[17] Lee SH,Noh KB,Lee JS,et al.Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin［J］.Lung Cancer,2013,81(1):102-108.
[18] Lin CS,Liu TC,Lai JC,et al.Evaluating the prognostic value of ERCC1 and thymidylate synthase expression and the epidermal growth factor receptor mutation status in adenocarcinoma non-small-cell lung cancer［J］.International Journal of Medical Sciences,2017,14(13):1410-1417.
[19] Jemal A,Bray F,Center MM,et al.Global cancer statistics［J］.CA:A Cancer Journal for Clinicians,2011,61(2):69-90.
[20] Shi Y,Wang L,Han B,et al.First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation(CONVINCE)［J］.Annals of Oncology,2016,34(15-suppl):9041.
[21] Yang JC,Wu YL,Schuler M,et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung3 and LUX-Lung6):Analysis of overall survival data from two randomised,phase 3 trials［J］.Lancet Oncology,2015,16(2):141-151.
[22] EL Kwak,DR Camidge,J Clark,et al.G6 clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor,PF-02341066［J］.J Clin Oncol,2009,27(15):3509.
[23] Shaw AT,Kim DW,Mehra R,et al.Ceritinib in ALK-rearranged non-small-cell lung cancer［J］.New England Journal of Medicine,2014,370(13):1189-1197.
[24] Solomon BJ,Mok T,Kim DW,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer［J］.N Engl J Med,2014,371(23):2167-2177.
[25] Kim D,Tiseo M,Ahn M,et al.Brigatinib(BRG) in patients(pts) with crizotinib(CRZ)-refractory ALK+ non-small cell lung cancer(NSCLC):First report of efficacy and safety from a pivotal randomized phase(ph) 2 trial(ALTA)［J］.J Clin Oncol,2016,34(suppl):9007.
[26] Kwak EL,Bang YJ,Camidge DR,et al.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer［J］.New England Journal of Medicine,2010,363(18):1693-1703.
[27] SI Ou,DR Camidge,JA Engeiman,et al.Clinical activity of crizotinib in advanced non-small cell lung cancer(NSCLC) harboring ROS1 gene rearrangement［C］.Vienna,Austria:European Society for Medical Oncology(ESMO),2012.
[28] Davies KD,Le AT,Theodoro MF,et al.Identifying and targeting ROS1 gene fusions in non-small cell lung cancer［J］.Clinical Cancer Research,2012,18(17):4570.
[29] Edelman MJ,Le CT,Soria JC.Maintenance therapy and advanced non-small-cell lung cancer:A skeptic's view［J］.Journal of Thoracic Oncology,2012,7(9):1331-1336.
备注/Memo
- 备注/Memo:
- 湖南省卫生计生委科研计划课题项目（编号： C2016095）
